IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

09/807,647

6/29/2001

ventor:

OI, Satoru

1,5-Benzodiazepine Compounds, Their Production and

Use

Atty. Dkt. No.

2560 US0P

Art Unit:

tba

Examiner:

tba

Allowed:

Batch:

Paper No.:

Supplemental Information Disclosure Statement

Commissioner for Patents P.O. BOX 1450 **ALEXANDRIA, VA 22313-1450**

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the reference listed on the attached Form PTO-1449.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call applicants' attorney at (847) 383-3372.

(847) 383-3372

(847) 383-3391

Respectfully submitted,

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Attorney for Applicants

Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department Suite 500, 475 Half Day Road Lincolnshire, IL 60069 USA

	٠,٠	OIL	E 707			(0				
Page 1 of 1		1	. W								
Page 1 of 1 FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMICS TRADITIONS PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)				ATTY DOCKET NO.: 2560US0P			SERIAL NO.: 09/807,647				
Date Submitted to PTO:											
					APPLICANT:O. SATORU						
				FILING DATE: GROUP: tb			OUP: tba				
					6/29/2001 Examiner tba						
CALERAN V D'ALL'ALEMAN	0000				TO DOCUMENTS		\sim		I		
OEXAMINER INITIAL	Ref No.	DOCUMENT NUMBER	DATE		NAME	CILAS	S	SUECLASS	IFILING DATE APPROPRIATI		
	Bl	5,739,129	4/1998		Aquino, et al.	514		221			
					-						
										·	
	.45	G 3	FOREIG	IN PAT	HAIL DOXCANALE	NALES SALES	a drama		9		
OEXAMINER INITIAL	ref No.	DOCÚMENT NÚMBER	DATE		COUNTRY	CILAS		SUBCLASS	TERANSLATIO THES 100	N **	
		,									
	a de la composición dela composición de la composición dela composición de la compos		-		470						
CEXAMINER	REF				XOCUMENTI(S) THITLE, DATE, I		ENII		*		
DUHILAIC	No>	2.28	<u> </u>				2			7%	
				 _				· - · · · · · · · · · · · · · · · · · · ·			
					<u>-</u> -					·	
								 			
EXAMINER:	EXAMINER: DATE CONSIDERED:										
*FXAMINER: Initial if reference concidered, whether or not citation is in conformance with MDER 600. Deculing through citation if an in-											

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IN THE UNITED STATES <u>PATENT</u> AND TRADEMARK OFFICE

Application No.:

09/807,647

Filed:

6/29/2001

1st Inventor:

OI, Satoru

For:

1,5-Benodiazepine Compounds, Their Production and Use

Atty. Dkt. No.

2560 US0P

Art Unit:

tba

Examiner:

tba

Allowed:

Batch:

Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 410709886 US

DATE IN:

January 30, 2004

Itemized Papers/Items:

- 1. This Certificate and Return Postcard (2 pages)
- 2. Transmittal Form (1 page X 2)
- 3. Supplemental Information Disclosure Statement (1 page) and Form PTO 1449 (1 page)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

on this date, 1/30/04

Dated: //30/04

Gail L. Winokur

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department Suite 500, 475 Half Day Road Lincolnshire, IL 60069 USA